Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05733312 · ClinicalTrials.gov registry record · NA
Extracellular Impact of Ultrasound-induced Blood-brain Barrier Disruption
A NA study of Brain Tumor, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT05733312: Recruiting NA study of Brain Tumor, sponsored by Mayo Clinic.
NCT05733312 is a NA study of Brain Tumor that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 6 participants, below the 282-participant average among 69 other Brain Tumor trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05733312, a NA study of Brain Tumor, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to determine the impact of focused ultrasound (FUS) on the composition of the tumor extracellular microenvironment. Researchers will evaluate regions that are very abnormal, as well as regions that have less evidence of disease. A sub-portion of each of these areas will be targeted by focused ultrasound. Microdialysis catheters will then be placd into each region that has and has not been exposed to FUS (total of 4 catheters) to determine how FUS impacts the the brain and tumor extracellular metabolome, including concentration of routine drugs systemically administered prior to, and during surgery. Researchers hope that this information will help reveal the relative contribution of blood-derived compounds to the tumor microenvironment. If successful, microdialysis could be leveraged in the future to simultaneously evaluate pharmacokinetic and pharmacodynamic impacts of future candidate therapies, including those delivered with the aid of FUS.
Primary Outcome
Number of adverse deemed related to FUS and/or intraoperative microdialysis after the integration of FUS and intraoperative microdialysis into the neurosurgical workflow for tumor resection
Conditions Studied
Interventions
- DEVICE InSightec's ExAblate Neuro Model 4000 Type 2.0 (220 KHz) system
Study Locations (1)
Minnesota
- Mayo Clinic Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2024-01-24 |
| Est. Completion | 2027-01-15 |
| Phase | NA |
What NCT05733312 shows while recruiting
NCT05733312 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 282-participant average among 69 other Brain Tumor trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which InSightec's ExAblate Neuro Model 4000 Type 2.0 (220 KHz) system is the first listed.
NCT05733312 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05733312 about?
NCT05733312 is a clinical study titled "Extracellular Impact of Ultrasound-induced Blood-brain Barrier Disruption". This study seeks to determine the impact of focused ultrasound (FUS) on the composition of the tumor extracellular microenvironment. Researchers will evaluate regions that are very abnormal, as well as regions that have less evidence of disease. A sub-portion of each of these areas will be targeted ...
What is the current status of trial NCT05733312?
This trial is currently recruiting. It is a NA study. The enrollment target is 6 participants. The study started on 2024-01-24. Estimated completion is 2027-01-15.
What conditions does trial NCT05733312 study?
This clinical trial studies the following conditions: Brain Tumor.
What interventions are being tested in trial NCT05733312?
The interventions under investigation include: InSightec's ExAblate Neuro Model 4000 Type 2.0 (220 KHz) system (DEVICE).
Who is sponsoring clinical trial NCT05733312?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05733312 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05733312's enrollment target sits among peer trials
6 68th of 69 higher than 1 of 69 other Brain Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Cognitive Training in the Virtual Reality Setting With Children Undergoing Radiotherapy for Brain Tumors
RECRUITING · NA
-
Ommaya Reservoir Placement for Brain Tumor Biomarker Access
RECRUITING · NA
-
Mapping of Human Cognition
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Recurrent Gliomas
RECRUITING · NA
-
Visual Plasticity Following Brain Lesions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI